| Team 1 : Robert Ballotti | |||
| BIOLOGY AND PATHOLOGY OF MELANOCYTE CELLS: FROM SKIN PIGMENTATION TO MELANOMAS | |||
| Previous activities | |||
Our work was focused on the study of the molecular mechanisms involved in melanocyte differentiation. The results we obtained were a major breakthrough in the understanding of the transcription mechanisms and the early signaling events that control the synthesis of melanin pigments and dendricity – both key parameters of melanocyte differentiation. We have shown the major role played by MITF transcription factor in such processes. We also studied melanosome transport, melanosomes being melanocyte-specific intracellular vesicles where melanin synthesis occurs. Melanosomes are transported to melanocyte' dendrites tips then transferred to neighboring keratinocytes, which results in an effective protection of melanin against carcinogenic UV rays. We have shown that the small G protein, Rab27a, plays a key role in melanosome transport.
More recently, we have developed new approaches focusing on the study of apoptosis and the microenvironment in which a melanoma develops. We have highlighted the key role of PI3-kinase pathway in SCF antiapoptotic effects and in melanoma resistance to chemotherapy drugs. Moreover, we have identified MITF as a new caspase substrate during apoptosis of melanocytes and melanomas. Finally, we have shown that MITF regulates at the transcription level the expression of HIF1α?, a transcription factor that plays a key role in neovascularization processes. We have been the first to describe the signaling pathways involved in the expression of fibronectin in melanomas. This pathway involves the activation of B-Raf and MAP kinases/ ERKs and triggers transcription factor Egr-1. Moreover, we have shown that the matrix protein SPARC, which expression increases during melanocyte tumour development regulates the early stages of melanocyte transformation by repressing E-cadherine and triggering a mesenchyme-type transition that is that hallmark of an invasive potential. These original findings suggest that SPARC plays a key role in melanocyte transformation.
|
|||
| Research Projects | |||
| I.
Role of MITF in melanoma survival and development |
|||
| II.
Role of FoxO proteins in melanoma survival and development |
|||
| III.
Role of SPARC in melanoma development . |
|||
| IV.
Role of Syk (Spleen tyrosine kinase) in melanoma development |
|||
| V-
Role of MITF and HIF1A in melanoma development |
|||
| VI-
Analysis of molecular events triggered by UV rays in melanocytes. |
|||
VII-
Role of PPARγ in melanocytes and melanomas and its involvement
in tumor development. Through their different yet complementary approaches, the projects developed under this program will contribute to the elucidation of the molecular processes controlling melanocyte differentiation, survival and transformation. The results will allow to better unserstand the mechanisms involved in melanin photoprotection, photocancerogenesis and the pathogenesis of skin pigmentation disorders. |
|||
| Major Publications | |||
|
2015 Larribere L, Wu H, Novak D, Galach M, Bernhardt M, Orouji E, Weina K, Knappe N, Sachpekidis C, Umansky L, Beckhove P, Umansky V, De Schepper S, Kaufmann D, Ballotti R, Bertolotto C, Utikal J. NF1 loss induces senescence during human melanocyte differentiation in an iPSC-based model. Pigment Cell Melanoma Res. 2015 Mar 30 2014 Lehraiki A, Abbe P, Cerezo M, Rouaud F, Regazzetti C, Chignon-Sicard B, Passeron T, Bertolotto C, Ballotti R, Rocchi S. Inhibition of Melanogenesis by the Antidiabetic Metformin. J Invest Dermatol. 2014 Apr 22. Ohanna M, Bonet C, Bille K, Allegra M, Davidson I, Bahadoran P, Lacour JP, Ballotti R, Bertolotto C. SIRT1 promotes proliferation and inhibits the senescence-like phenotype in human melanoma cells. Oncotarget. 2014 Feb 19. Cerezo M, Tomic T, Ballotti R, Rocchi S. Is it time to test biguanide metformin in the treatment of melanoma? Pigment Cell Melanoma Res. 2014 May 24. Cheli Y, Bonnazi VF, Jacquel A, Allegra M, De Donatis GM, Bahadoran P, Bertolotto C, Ballotti R. CD271 is an imperfect marker for melanoma initiating cells. Oncotarget. 2014 Jul 30;5(14):5272-83. Rouaud F, Romero-Perez M, Wang H, Lobysheva I, Ramassamy B, Henry E, Tauc P, Giacchero D, Boucher JL, Deprez E, Rocchi S, Slama-Schwok A. Regulation of NADPH-dependent Nitric Oxide and reactive oxygen species signalling in endothelial and melanoma cells by a photoactive NADPH analogue. Oncotarget. 2014 Sep 25. 2013 Ohanna M, Cheli Y, Bonet C, Bonazzi VF, Allegra M, Giuliano S, Bille K, Bahadoran P, Giacchero D, Lacour JP, Boyle GM, Hayward NF, Bertolotto C, Ballotti R. Secretome from senescent melanoma engages the STAT3 pathway to favor reprogramming of naive melanoma towards a tumor-initiating cell phenotype. Oncotarget. 2013 Dec;4(12):2212-24. Allegra M, Giacchero D, Segalen C, Dumaz N, Butori C, Hofman V, Hofman P, Lacour JP, Bertolotto C, Bahadoran P, Ballotti R. A New KIT Mutation (N505I) in Acral Melanoma Confers Constitutive Signaling, Favors Tumorigenic Properties, and Is Sensitive to Imatinib. J Invest Dermatol. 2013 Dec Bertolotto C. Melanoma: From Melanocyte to Genetic Alterations and Clinical Options. Scientifica (Cairo). 2013;2013:635203. Cerezo M, Tichet M, Abbe P, Ohanna M, Lehraiki A, Rouaud F, Allegra M, Giacchero D, Bahadoran P, Bertolotto C, Tartare-Deckert S, Ballotti R, Rocchi S. Metformin Blocks Melanoma Invasion and Metastasis Development in AMPK/p53-Dependent Manner. Mol Cancer Ther. 2013 Aug 1. [Epub ahead of print] PubMed PMID: 23741061. Bahadoran P, Allegra M, Le Duff F, Long-Mira E, Hofman P, Giacchero D, Passeron T, Lacour JP, Ballotti R. Major Clinical Response to a BRAF Inhibitor in a Patient With a BRAF L597R-Mutated Melanoma. J Clin Oncol. 2013 Jul 1;31(19):e324-6. doi: 10.1200/JCO.2012.46.1061. Epub 2013 May 28. PubMed PMID: 23715574. Botton T, Yeh I, Nelson T, Vemula SS, Sparatta A, Garrido MC, Allegra M, Rocchi S, Bahadoran P, McCalmont TH, Leboit PE, Burton EA, Bollag G, Ballotti R, Bastian BC. Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy. Pigment Cell Melanoma Res. 2013 Jul 24 2012 Fenouille N, Tichet M, Dufies M, Pottier A, Mogha A, Soo JK, Rocchi S, Mallavialle A, Galibert MD, Khammari A, Lacour JP, Ballotti R, Deckert M, Tartare-Deckert S. The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion. PLoS One. 2012;7(7) Bonet C, Giuliano S, Ohanna M, Bille K, Allegra M, Lacour JP, Bahadoran P, Rocchi S, Ballotti R, Bertolotto C. Aurora B is regulated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway and is a valuable potential target in melanoma cells. J Biol Chem. 2012 Aug 24;287(35):29887-98 Chiaverini C, Sillard L, Flori E, Ito S, Briganti S, Wakamatsu K, Fontas E, Berard E, Cailliez M, Cochat P, Foulard M, Guest G, Niaudet P, Picardo M, Bernard FX, Antignac C, Ortonne JP, Ballotti R. Cystinosin is a melanosomal protein that regulates melanin synthesis. FASEB J. 2012 Sep;26(9):3779-89. doi: 10.1096/fj.11-201376 Bertolotto C, Lesueur F, Bressac de Paillerets B. [MITF: a genetic key to melanoma and renal cell carcinoma?]. Med Sci (Paris). 2012 Mar;28(3):258-61 Puissant A, Dufies M, Fenouille N, Ben Sahra I, Jacquel A, Robert G, Cluzeau T, Deckert M, Tichet M, Chéli Y, Cassuto JP, Raynaud S, Legros L, Pasquet JM, Mahon FX, Luciano F, Auberger P. Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness. J Mol Cell Biol. 2012 Aug;4(4):207-20 2011 Passeron T, Lacour JP, Allegra M, Ségalen C, Deville A, Thyss A, Giacchero D, Ortonne JP, Bertolotto C, Ballotti R, Bahadoran P. Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy? Exp Dermatol. 2011 Dec;20(12):1030-2. Bertolotto C, Lesueur F, Giuliano S, Strub T, de Lichy M, Bille K, Dessen P, d'Hayer B, Mohamdi H, Remenieras A, Maubec E, de la Fouchardière A, Molinié V, Vabres P, Dalle S, Poulalhon N, Martin-Denavit T, Thomas L, Andry-Benzaquen P, Dupin N, Boitier F, Rossi A, Perrot JL, Labeille B, Robert C, Escudier B, Caron O, Brugières L, Saule S, Gardie B, Gad S, Richard S, Couturier J, Teh BT, Ghiorzo P, Pastorino L, Puig S, Badenas C, Olsson H, Ingvar C, Rouleau E, Lidereau R, Bahadoran P, Vielh P, Corda E, Blanché H, Zelenika D, Galan P; French Familial Melanoma Study Group, Aubin F, Bachollet B, Becuwe C, Berthet P, Bignon YJ, Bonadona V, Bonafe JL, Bonnet-Dupeyron MN, Cambazard F, Chevrant-Breton J, Coupier I, Dalac S, Demange L, d'Incan M, Dugast C, Faivre L, Vincent-Fétita L, Gauthier-Villars M, Gilbert B, Grange F, Grob JJ, Humbert P, Janin N, Joly P, Kerob D, Lasset C, Leroux D, Levang J, Limacher JM, Livideanu C, Longy M, Lortholary A, Stoppa-Lyonnet D, Mansard S, Mansuy L, Marrou K, Matéus C, Maugard C, Meyer N, Nogues C, Souteyrand P, Venat-Bouvet L, Zattara H, Chaudru V, Lenoir GM, Lathrop M, Davidson I, Avril MF, Demenais F, Ballotti R, Bressac-de Paillerets B. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature. 2011 Oct 19;480(7375):94-8. Cheli Y, Giuliano S, Fenouille N, Allegra M, Hofman V, Hofman P, Bahadoran P, Lacour JP, Tartare-Deckert S, Bertolotto C, Ballotti R. Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells. Oncogene. 2011 Sep 26. Chiavérini C, Kang HY, Sillard L, Berard E, Niaudet P, Guest G, Cailliez M, Bahadoran P, Lacour JP, Ballotti R, Ortonne JP. In vivo reflectance confocal microscopy of the skin: A noninvasive means of assessing body cystine accumulation in infantile cystinosis. J Am Acad Dermatol. 2011 Sep 30. Tomic T, Botton T, Cerezo M, Robert G, Luciano F, Puissant A, Gounon P, Allegra M, Bertolotto C, Bereder JM, Tartare-Deckert S, Bahadoran P, Auberger P, Ballotti R, Rocchi S. Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis. 2011 Sep 1;2 Luciani F, Champeval D, Herbette A, Denat L, Aylaj B, Martinozzi S, Ballotti R, Kemler R, Goding CR, De Vuyst F, Larue L, Delmas V. Biological and mathematical modeling of melanocyte development. Development. 2011 Sep;138(18):3943-54. Javelaud D, Alexaki VI, Pierrat MJ, Hoek KS, Dennler S, Van Kempen L, Bertolotto C, Ballotti R, Saule S, Delmas V, Mauviel A. GLI2 and M-MITF transcription factors control exclusive gene expression programs and inversely regulate invasion in human melanoma cells. Pigment Cell Melanoma Res. 2011 Oct;24(5):932-43. Ohanna M, Giuliano S, Bonet C, Imbert V, Hofman V, Zangari J, Bille K, Robert C, Bressac-de Paillerets B, Hofman P, Rocchi S, Peyron JF, Lacour JP, Ballotti R, Bertolotto C. Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS). Genes Dev. 2011 Jun 15;25(12):1245-61. doi: 10.1101/gad.625811. Epub 2011 Jun 6. Bourcier C, Griseri P, Grépin R, Bertolotto C, Mazure N, Pagès G. Constitutive ERK activity induces downregulation of tristetraprolin, a major protein controlling interleukin8/CXCL8 mRNA stability in melanoma cells. Am J Physiol Cell Physiol. 2011 Sep;301(3):C609-18. Beuret L, Ohanna M, Strub T, Allegra M, Davidson I, Bertolotto C, Ballotti R. BRCA1 is a new MITF target gene. Pigment Cell Melanoma Res. 2011 Aug;24(4):725-7. Chazenbalk G, Bertolotto C, Heneidi S, Jumabay M, Trivax B, Aronowitz J, Yoshimura K, Simmons CF, Dumesic DA, Azziz R. Novel pathway of adipogenesis through cross-talk between adipose tissue macrophages, adipose stem cells and adipocytes: evidence of cell plasticity. PLoS One. 2011 Mar 31;6(3):e17834. Cheli Y, Giuliano S, Botton T, Rocchi S, Hofman V, Hofman P, Bahadoran P, Bertolotto C, Ballotti R. Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny. Oncogene. 2011 May 19;30(20):2307-18. Epub 2011 Jan 31. Erratum in: Oncogene. 2011 May 19;30(20):2390. Guiliano, S [corrected to Giuliano, S]. Strub T, Giuliano S, Ye T, Bonet C, Keime C, Kobi D, Le Gras S, Cormont M, Ballotti R, Bertolotto C, Davidson I. Essential role of microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma. Oncogene. 2011 May 19;30(20):2319-32. Giuliano S, Ohanna M, Ballotti R, Bertolotto C. Advances in melanoma senescence and potential clinical application. Pigment Cell Melanoma Res. 2011 Apr;24(2):295-308. doi: 10.1111/j.1755-148X.2010.00820.x. Epub 2011 Jan 11. Review. Ohanna M, Bertolotto C, Ballotti R. Fitting MITF regulation of PDE4D3 into the skin pigmentation puzzle. Pigment Cell Melanoma Res. 2011 Feb;24(1):4-6. 2010 Ohanna M, Bertolotto C, Ballotti R : Fitting MITF regulation of PDE4D3 into the skin pigmentation puzzle. Pigment Cell Melanoma Res. 2010 Oct 28 Fenouille N, Robert G, Tichet M, Puissant A, Dufies M, Rocchi S, Ortonne JP, Deckert M, Ballotti R, Tartare-Deckert S : The p53/p21(Cip1/ Waf1) pathway mediates the effects of SPARC on melanoma cell cycle progression. Pigment Cell Melanoma Res. 2010 Oct 18 Alexaki VI, Javelaud D, Van Kempen LC, Mohammad KS, Dennler S, Luciani F, Hoek KS, Juàrez P, Goydos JS, Fournier PJ, Sibon C, Bertolotto C, Verrecchia F, Saule S, Delmas V, Ballotti R, Larue L, Saiag P, Guise TA, Mauviel A : 3.GLI2-mediated melanoma invasion and metastasis. J Natl Cancer Inst. 2010 Aug 4;102(15):1148-59. Botton T, Puissant A, Cheli Y, Tomic T, Giuliano S, Fajas L, Deckert M, Ortonne JP, Bertolotto C, Tartare-Deckert S, Ballotti R, Rocchi S : Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth. Cell Death Differ. 2010 Jul 2. Giuliano S, Cheli Y, Ohanna M, Bonet C, Beuret L, Bille K, Loubat A, Hofman V, Hofman P, Ponzio G, Bahadoran P, Ballotti R, Bertolotto C.: Microphthalmia-Associated Transcription Factor Controls the DNA Damage Response and a Lineage-Specific Senescence Program in Melanomas. Cancer Res. 2010 Apr 13. Cheli Y, Williams SA, Ballotti R, Nugent DJ, Kunicki TJ : Enhanced binding of poly(ADP-ribose)polymerase-1 and Ku80/70 to the ITGA2 promoter via an extended cytosine-adenosine repeat. PLoS One. 2010 Jan 15;5(1):e8743. Cheli Y, Ohanna M, Ballotti R, Bertolotto C : Fifteen-year quest for microphthalmia-associated transcription factor target genes. Pigment Cell Melanoma Res. 2010 Feb;23(1):27-40. Review 2009 Gialanella B, Mattioli F, Rocchi S, Ferlucci C: Verbal intelligence in Neglect: the role of anosognosia for hemiplegia. Eur J Phys Rehabil Med 2009. Chéli Y, Luciani F, Khaled M, Beuret L, Bille K, Goudon P, Ortonne JP, Bertolotto C, Ballotti R. Alpha-MSH and cyclic-AMP elevating agents control melanosome pH through a PKA-independent mechanism. J Biol Chem, 2009, 284:18699-18706.
Arrault A, Rocchi S, Picard F, Maurois P, Pirotte B, Vamecq J: A short series of antidiabetic sulfonylureas exhibit multiple ligand PPARgamma-binding patterns. Biomed Pharmacother, 2009, 63: 56-62.
2008 Bailet O, Fenouille N, Abbe P, Robert G, Rocchi S, Gonthier N, Denoyelle C, Ticchioni M, Ortonne JP, Ballotti R, Deckert M, and Tartare-Deckert S. Syk functions as a tumor suppressor in melanoma cells by inducing senescence-like growth arrest. Cancer Res., 2008, In press. Bertolotto C. [Beta-catenin and N-ras: a dangerous association for melanocytes]. Med Sci (Paris), 2008, 24:122-123. Botton T, Puissant A, Bahadoran P, Annicotte JB, Fajas L, Ortonne JP, Gozzerino G, Zamoum T, Tartare-Deckert S, Bertolotto C, Ballotti R and Rocchi S. In vitro and in vivo anti-melanoma effects of ciglitazone. J. Invest.Dermatol, 2008, In press. Chiaverini C, Beuret L, Flori E, Busca R, Abbe P, Bille K, Bahadoran P, Ortonne JP, Bertolotto C, and Ballotti R.. Microphthalmia-associated transcription factor regulates RAB27A gene expression and controls melanosome transport. J Biol Chem., 2008, 283:12635-12642. Cribier B, Chiaverini C, Dali-Youcef N, Schmitt M, Grima M, Hirth C, Lacour JP and Chosidow O. Porphyria cutanea tarda, hepatitis C, uroporphyrinogen decarboxylase and mutations of HFE gene. A case-control study. Dermatology. 2009, 218:15-21. Dahlman-Ghozlan K, Ortonne JP, Bahadoran P, Spadafora A and Stephansson E. Low-dose oral methotrexate induces apoptosis of tissue eosinophils in bullous pemphigoid. Acta Derm Venereol., 2008, 88:219-22. Del Giudice P, Blanc-Amrane V, Bahadoran P, Caumes E, Marty P, Lazar M, Boissy C, Desruelles F, Izri A, Ortonne JP, Counillon E, Chosidow O and Delaunay P. Pyemotes ventricosus dermatitis, southeastern France. Emerg Infect Dis., 2008, 14:1759-1761. Demozay D, Mas JC, Rocchi S and Van Obberghen E. FALDH reverses the deleterious action of oxidative stress induced by lipid peroxidation product 4-hydroxynonenal on insulin signaling in 3T3-L1 adipocytes. Diabetes., 2008, 57:1216-1226. Giacchero D, Monpoux F, Chiaverini C, and Lacour JP. [6-mercaptopurine-related
hand-foot syndrome in a four-year-old child]. Ann Dermatol Venereol.
, 2008, 135:580-3. Hilmi C, Larribere L, Deckert M, Rocchi S, Giuliano S, Bille K, Ortonne JP, Ballotti R and Bertolotto C.. Involvement of FKHRL1 in melanoma cell survival and death. Pigment Cell Melanoma Res, 2008, 21:139-146. Hilmi C, Larribere L, Giuliano S, Bille K, Ortonne JP, Ballotti R, and Bertolotto C. IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCL-X(L), and survivin. J Invest Dermatol., 2008, 128:1499-1505. Jemec G.B, Ganslandt C, Ortonne JP, Poulin Y, Burden AD, de Unamuno P, Berne B, Figueiredo A, and Austad J. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. J Am Acad Dermatol. , 2008, 59:455-463. Maurer M, Ortonne JP, and Zuberbier T. Chronic urticaria: an internet survey of health behaviours, symptom patterns and treatment needs in European adult patients. Br J Dermatol., 2008. Maurois P, Rocchi S, Pages N, Bac P, Stables JP, Gressens p, and Vamecq J. The PPARgamma agonist FMOC-L-leucine protects both mature and immature brain. Biomed Pharmacother., 2008, 62:259-263. Ortonne JP and Bissett DL. Latest insights into skin hyperpigmentation. J Investig Dermatol Symp Proc., 2008, 13:10-14. Ortonne JP, Zartarian M, Verschoore M, Queille-Roussel C and Duteil L. 2008. Cellulite and skin ageing: is there any interaction? J Eur Acad Dermatol Venereol. 22:827-834. Ortonne JP. [Normal and abnormal human skin colour: from research to aesthetics]. Ann Dermatol Venereol., 2008, 135 Suppl 3:S153-156. Ortonne JP. [Psoriasis, metabolic syndrome and its components]. Ann Dermatol Venereol. , 2008, 135 Suppl 4:S235-242. Ortonne JP. [What are the objectives of moderate to severe psoriasis treatment?]. Ann Dermatol Venereol., 2008, 135 Suppl 5:S281-284. Revicki D, Willian MK, Saurat JH, Papp KA, Ortonne JP, Sexton C and Camez A. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol., 2008, 158:549-557. Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, Unnebrink K, Kaul M and Camez A. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol., 2008, 158:558-566. Schallreuter KU, Bahadoran P, Picardo M, Slominski A, Elassiuty YE, Kemp EH, Giachino C, Liu JB, Luiten RM, Lambe T, Le Poole IC, Dammak I, Onay H, Zmijewski MA, Dell'Anna ML, Zeegers MP, Cornall RJ, Paus R, Ortonne JP and Westerhof W. Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp Dermatol., 2008, 17:139-140; discussion 141-160. Szeimies RM, Bichel J, Ortonne JP, Stockfleth E, Lee J and Meng TC. A phase II dose-ranging study of topical resiquimod to treat actinic keratosis. Br J Dermatol., 2008, 159:205-210. Yamaguchi Y, Passeron T, Hoashi T, Watabe H, Rouzaud F, Yasumoto
K, Hara T, Tohyama C, Katayama I, Miki T and Hearing VJ. Dickkopf
1 (DKK1) regulates skin pigmentation and thickness by affecting Wnt/beta-catenin
signaling in keratinocytes. Faseb J., 2008, 22:1009-1020. Previous publications Robert
G, Gaggioli C,
Bailet O, Chavey
C, Abbe P, Aberdam E, Sabatie E, Cano A, Garcia de Herreros A,
Ballotti R, Tartare-Deckert S. (2005) SPARC represses E-cadherin
and induces mesenchymal transition during melanoma development. Cancer
Res,
66, 7516-7523. |
|||
 |
 |
 |
|
| Home | Top of page | Publications | |
| Team leader | ||||||
|---|---|---|---|---|---|---|
 |
||||||
| ballotti@unice.fr | ||||||
| Researcher | ||||||
 R.
BALLOTTI |
||||||
| C.
BERTOLOTTO |
||||||
| S.ROCCHI |
M.
OHANNA |
|||||
| Clinical researcher | ||||||
| P.
BAHADORAN |
||||||
| J.P.
ORTONNE |
||||||
| Postdoc | ||||||
| A. LEHRAIKI |
||||||
| JF OTTAVI |
||||||
| N HABEL |
||||||
| C GAUDEL |
||||||
| Student | ||||||
| E.
JAUNE |
||||||
| F.
ROUAUD |
||||||
| N.
El HACHEM |
||||||
| R.
DIDIER |
||||||
| Research assistant | ||||||
| P.
ABBE |
||||||
| K.BILLE |
||||||
| G. SALEZ |
||||||
| M. BONCOMPAGNI |
||||||
| T NAIKEN |
||||||
|
||||||
 |
||||||
| Marking of a métastase ganglionaire of mélanome by antibodies anti-Phospho-ERK | ||||||